M1 Kliniken AG

  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 10.04.2019 | 09:30

M1 Kliniken AG expands market leadership in the field of beauty medicine and starts international expansion

DGAP-News: M1 Kliniken AG / Key word(s): Expansion

10.04.2019 / 09:30
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG expands market leadership in the field of beauty medicine and starts international expansion

- Number of specialist centres rises from 17 to 24

- Successful start to international expansion and entry into new attractive fields of treatment

- Positive outlook: business volume to be further increased

Berlin, 10.04.2019 - M1 Kliniken AG (ISIN: DE000A0STSQ8) has continued its profitable growth course in 2018 and invested considerably in further growth. As the leading private German provider of health services in the field of beauty medicine, the group of companies benefits from the increasing demand for plastic and aesthetic treatments.

In the M1 specialist centres, the number of treatments performed in the 2018 financial year was increased to just under 190,000. The strong growth is attributable in particular to existing and new locations of M1 Med Beauty. After six new openings in 2017, seven locations were added in 2018 (in Frankfurt and Cologne, the company moved to larger premises). M1 Med Beauty thus had 24 specialist centres in 19 cities at the end of the year. These include the first international specialist centre in Vienna.

"In 2018, we expanded our market leadership in Germany, added two new market segments with great potential to our range of services and started the international rollout," says Patrick Brenske, CEO of M1 Kliniken AG. "We see great potential in virtually every country in Western Europe. For the most part, the prices for cosmetic surgery are too high and we can quickly achieve a high market share with our established business model. At the same time, we are expanding the respective market by offering high-quality beauty treatments at an attractive price and thus making them accessible to more people."

M1 also has considerable growth opportunities in Germany. In addition to new locations of the core brand "M1 Med Beauty", the new brands "M1 Laser" and "M1 Dental" will contribute to this in the future. With them, M1 is expanding its range of services to include dermatological laser and aesthetic dental treatments. In Germany alone, around 12 million cosmetic laser treatments are carried out annually and the market volume for dental aesthetics is estimated at around 3.0 billion euros. Since M1 Laser will be integrated into the existing beauty locations, growth will be fast and cost-efficient. At the end of the first quarter of 2019, laser treatments were already available at nine M1 Med Beauty locations and are to be offered successively in all specialist centres. Following the opening of the first treatment centre for aesthetic dentistry in 2018 within the M1 Schlossklinik in Berlin, M1 Dental locations in Munich, Frankfurt and Hamburg have now been added.

"The opening of new specialist centres in 2018 alone has already secured significant growth in the current year. In addition, we will continue to invest in order to consistently utilize our market opportunities and achieve our targets for 2020," says Dr. Walter von Horstig, board member of M1 Kliniken AG. The Group plans to double the number of M1 Med Beauty specialist centres to around 50 by the end of 2020. Around 30 of these will be located in Germany and 20 in other European countries. Concrete preparations are already underway in Switzerland, the Netherlands and the UK. The integration of M1 Laser will further increase the profitability of the locations. In addition, M1 Dental will be available throughout Germany.

The scope of the activities required to prepare the consolidated financial statements of M1 Kliniken AG has increased significantly due to the rapid growth of the group of companies last year. The audited 2018 financial statements of M1 Kliniken AG are expected to be published on May 21, 2019.

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medicine health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality. Under the brands M1 Med Beauty, M1 Laser and M1 Dental, beauty medical treatments are currently offered at more than 25 locations. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. In addition, the Group markets high-quality products to private customers, doctors, pharmacies and wholesalers under the M1 Select and M1 Aesthetics brands. www.m1-kliniken.de


M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Phone: +49 (0)30 347 47 44 14
E-mail: ir@m1-kliniken.de

10.04.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

Interview im Fokus

„Schnelleres Wachstum mit Wasserstoff“

Mit dem Einstieg in die Wasserstoff-Technologie erschließt sich SFC Energy ein besonders dynamisches Segment. „Mittelfristig ist das Marktvolumen für Wasserstoff-Brennstoffzellen noch größer als im Direkt-Methanol-Bereich. Zivile Massenanwendungen könnten sich dabei zu einem echten Wachstumsbooster entwickeln“, ist CEO Dr. Peter Podesser überzeugt. Im Financial.de-Interview spricht der SFC-Vorstandschef u. a. über die aktuelle Euphorie für Brennstoffzellen-Aktien, die geplante Kapitalmaßnahme und das mittelfristige Umsatzziel von 100 Mio. Euro.


Studie GBC Best of m:access I.2019: Weiter im Aufwind und mit starker Outperformance

Das Qualitätssegment m:access hat sich in den letzten Jahren fulminant entwickelt und ist auch 2018 weiter gewachsen. Zuletzt umfasste der m:access einen Rekordwert von 60 Unternehmen unterschiedlichster Branchen mit einer Gesamtmarktkapitalisierung von rund EUR 12 Mrd. Der von GBC berechnete m:access Index hat im Betrachtungszeitraum eine starke Outperformance gezeigt. Auch für die neue Top 15 Best-Of-Auswahl sind die Analysten wieder sehr positiv gestimmt. Die Studie steht kostenlos zum Download zur Verfügung.

News im Fokus

Linde Signs Long-Term Agreement with ExxonMobil to Supply Integrated Manufacturing Complex in Singapore

25. Juni 2019, 13:00

Aktueller Webcast

Stealth BioTherapeutics

The BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference

25. Juni 2019

Aktuelle Research-Studie

euromicron AG

Original-Research: euromicron AG (von GBC AG): Buy

26. Juni 2019